Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Department of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.
Biochem Biophys Res Commun. 2019 Jun 30;514(3):791-797. doi: 10.1016/j.bbrc.2019.05.015. Epub 2019 May 10.
Blockers of G-protein coupled receptors (GPCRs), angiotensin II (Ang II) type 1 (AT) receptor and β-adrenergic (Ad) receptor, have been shown to improve the prognosis of cardiovascular disease. Cholesterol molecules in the cell membrane are needed to stabilize GPCRs as well as the cell membrane itself. We determined whether the functions of AT and β-Ad receptors were changed by cholesterol depletion from cardiovascular cell membranes. Ang II-induced inositol phosphate production through AT receptor was suppressed by cholesterol depletion from cell membranes using rosuvastatin or methyl-β-cyclodextrin (MβCD), whereas isoproterenol-induced cyclic AMP production through β-Ad receptor did not change after cholesterol depletion. In addition, the binding affinities of Ang II and AT receptor blocker after cholesterol depletion were significantly lower than those before depletion. Although AT receptor expression levels did not change after cholesterol depletion, the expression levels of AT receptor that could bind to Ang II significantly decreased after depletion. The changes in the structure of AT receptor due to depletion were confirmed by substituted-cysteine accessibility mapping. In conclusion, Ang II-induced activation of AT receptor is reduced without affecting the function of β-Ad receptor after cholesterol depletion from cardiovascular cell membranes.
G 蛋白偶联受体 (GPCR)、血管紧张素 II (Ang II) 型 1 (AT) 受体和β-肾上腺素能 (Ad) 受体的阻滞剂已被证明可改善心血管疾病的预后。细胞膜中的胆固醇分子对于稳定 GPCR 以及细胞膜本身都是必需的。我们确定了通过从心血管细胞膜中去除胆固醇是否会改变 AT 和 β-Ad 受体的功能。使用瑞舒伐他汀或甲基-β-环糊精 (MβCD) 从细胞膜中去除胆固醇会抑制 Ang II 通过 AT 受体诱导的肌醇磷酸盐产生,而胆固醇耗尽后β-Ad 受体诱导的环 AMP 产生没有变化。此外,胆固醇耗尽后 Ang II 和 AT 受体阻滞剂的结合亲和力明显低于耗尽前。尽管胆固醇耗尽后 AT 受体表达水平没有变化,但与 Ang II 结合的 AT 受体表达水平在耗尽后显著降低。通过取代半胱氨酸可及性映射证实了 AT 受体结构的变化。总之,从心血管细胞膜中去除胆固醇后,Ang II 诱导的 AT 受体激活减少,而β-Ad 受体的功能不受影响。